Summary & Overview
CPT 83884: Neurofilament Light Chain (NfL) Assay
CPT code 83884 represents a laboratory chemistry assay for neurofilament light chain (NfL), a blood- or CSF-based biomarker that can indicate neuronal injury across a range of neurological disorders. Nationally, NfL testing has clinical significance for neurology, neurodegenerative disease management, and research into inflammatory and traumatic brain conditions. Rising clinical interest in NfL testing has driven payer attention to coverage policies and reimbursement approaches.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical role, common billing considerations, and the payer landscape. The publication outlines what types of services and sites typically use this code, common modifiers and service line notes (where available), and how NfL testing fits into broader laboratory and neurology practice patterns.
This summary provides practical context for clinicians, laboratory billing staff, and policy analysts: understanding the clinical indications for NfL testing, typical places of service, and the payer groups commonly involved. Data not available in the input for specific taxonomies, ICD-10 pairings, and related codes is noted elsewhere in the full publication.
Billing Code Overview
CPT code 83884 describes a laboratory chemistry test that measures neurofilament light chain (NfL) levels. The assay is performed by a lab analyst and is used to detect elevated NfL, a biomarker associated with neuronal injury and several neurological conditions.
Service Type: Laboratory chemistry testing for neurofilament light chain
Typical Site of Service: Clinical laboratory or hospital laboratory setting, including specialized neurodiagnostic or reference laboratories.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult referred by a neurologist for laboratory assessment of neuroaxonal injury. The patient presents with subacute cognitive decline, new-onset gait instability, or suspected inflammatory or degenerative neurologic disease. A serum or cerebrospinal fluid sample is collected in an outpatient infusion center, hospital phlebotomy lab, or inpatient ward and sent to a clinical chemistry laboratory. The lab analyst performs an assay to quantify neurofilament light chain (NfL) using immunoassay or ultrasensitive platforms. Results are reported to the ordering provider and used as a biomarker to help assess disease activity, progression, or treatment response in conditions such as multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer disease, and other neurodegenerative or inflammatory neuropathies. Typical sites of service: hospital outpatient laboratory, independent clinical laboratory, hospital inpatient laboratory, and ambulatory clinic with specimen transport to a reference lab. Common workflow steps: order placed by neurologist or primary care clinician; specimen collection and labeling; transport to lab; analytic run and quality controls; result validation and reporting to the clinician; incorporation into longitudinal clinical assessment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Default/No modifier | Use when no additional modifier applies to the laboratory service. |